These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1110 related articles for article (PubMed ID: 17721369)

  • 21. Recommendations for the prevention of Streptococcus pneumoniae infections in infants and children: use of 13-valent pneumococcal conjugate vaccine (PCV13) and pneumococcal polysaccharide vaccine (PPSV23).
    American Academy of Pediatrics Committee on Infectious Diseases
    Pediatrics; 2010 Jul; 126(1):186-90. PubMed ID: 20498180
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The changing epidemiology of invasive pneumococcal disease in aboriginal and non-aboriginal western Australians from 1997 through 2007 and emergence of nonvaccine serotypes.
    Lehmann D; Willis J; Moore HC; Giele C; Murphy D; Keil AD; Harrison C; Bayley K; Watson M; Richmond P
    Clin Infect Dis; 2010 Jun; 50(11):1477-86. PubMed ID: 20420501
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Evolving picture of invasive pneumococcal disease in massachusetts children: a comparison of disease in 2007-2009 with earlier periods.
    Yildirim I; Stevenson A; Hsu KK; Pelton SI
    Pediatr Infect Dis J; 2012 Oct; 31(10):1016-21. PubMed ID: 22673142
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Impact of the pneumococcal conjugate vaccine on pneumococcal parapneumonic empyema.
    Byington CL; Korgenski K; Daly J; Ampofo K; Pavia A; Mason EO
    Pediatr Infect Dis J; 2006 Mar; 25(3):250-4. PubMed ID: 16511389
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Incidence of invasive pneumococcal disease among individuals with sickle cell disease before and after the introduction of the pneumococcal conjugate vaccine.
    Halasa NB; Shankar SM; Talbot TR; Arbogast PG; Mitchel EF; Wang WC; Schaffner W; Craig AS; Griffin MR
    Clin Infect Dis; 2007 Jun; 44(11):1428-33. PubMed ID: 17479937
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Reduction in the incidence of invasive pneumococcal disease after general vaccination with 7-valent pneumococcal conjugate vaccine in Germany.
    Rückinger S; van der Linden M; Reinert RR; von Kries R; Burckhardt F; Siedler A
    Vaccine; 2009 Jun; 27(31):4136-41. PubMed ID: 19406190
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Invasive pneumococcal disease in Alaskan children: impact of the seven-valent pneumococcal conjugate vaccine and the role of water supply.
    Wenger JD; Zulz T; Bruden D; Singleton R; Bruce MG; Bulkow L; Parks D; Rudolph K; Hurlburt D; Ritter T; Klejka J; Hennessy T
    Pediatr Infect Dis J; 2010 Mar; 29(3):251-6. PubMed ID: 19952861
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Geographic variation in invasive pneumococcal disease following pneumococcal conjugate vaccine introduction in the United States.
    Rosen JB; Thomas AR; Lexau CA; Reingold A; Hadler JL; Harrison LH; Bennett NM; Schaffner W; Farley MM; Beall BW; Moore MR;
    Clin Infect Dis; 2011 Jul; 53(2):137-43. PubMed ID: 21690620
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effectiveness of the 7-valent pneumococcal conjugate vaccine: a population-based case-control study.
    Barricarte A; Castilla J; Gil-Setas A; Torroba L; Navarro-Alonso JA; Irisarri F; Arriazu M
    Clin Infect Dis; 2007 Jun; 44(11):1436-41. PubMed ID: 17479939
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Invasive pneumococcal disease in young children before licensure of 13-valent pneumococcal conjugate vaccine - United States, 2007.
    Centers for Disease Control and Prevention (CDC)
    MMWR Morb Mortal Wkly Rep; 2010 Mar; 59(9):253-7. PubMed ID: 20224541
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effectiveness of a 2+1 dose schedule pneumococcal conjugate vaccination programme on invasive pneumococcal disease among children in Norway.
    Vestrheim DF; Løvoll O; Aaberge IS; Caugant DA; Høiby EA; Bakke H; Bergsaker MR
    Vaccine; 2008 Jun; 26(26):3277-81. PubMed ID: 18456376
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Nearly complete elimination of the 7-valent pneumococcal conjugate vaccine serotypes in Tennessee.
    Halasa NB; Grijalva CG; Arbogast PG; Talbot TR; Craig AS; Griffin MR; Schaffner W
    Pediatr Infect Dis J; 2013 Jun; 32(6):604-9. PubMed ID: 23348816
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Invasive pneumococcal disease and 13-valent pneumococcal conjugate vaccine (PCV13) coverage among children aged ≤59 months---selected U.S. regions, 2010--2011.
    Centers for Disease Control and Prevention (CDC)
    MMWR Morb Mortal Wkly Rep; 2011 Nov; 60(43):1477-81. PubMed ID: 22048728
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Direct and indirect effects of routine vaccination of children with 7-valent pneumococcal conjugate vaccine on incidence of invasive pneumococcal disease--United States, 1998-2003.
    Centers for Disease Control and Prevention (CDC)
    MMWR Morb Mortal Wkly Rep; 2005 Sep; 54(36):893-7. PubMed ID: 16163262
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Serotype coverage of invasive and mucosal pneumococcal disease in Israeli children younger than 3 years by various pneumococcal conjugate vaccines.
    Shouval DS; Greenberg D; Givon-Lavi N; Porat N; Dagan R
    Pediatr Infect Dis J; 2009 Apr; 28(4):277-82. PubMed ID: 19258924
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Invasive pneumococcal disease in Danish children, 1996-2007, prior to the introduction of heptavalent pneumococcal conjugate vaccine.
    Winther TN; Kristensen TD; Kaltoft MS; Konradsen HB; Knudsen JD; Høgh B
    Acta Paediatr; 2009 Feb; 98(2):328-31. PubMed ID: 18983440
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Eradication of invasive pneumococcal disease due to the seven-valent pneumococcal conjugate vaccine serotypes in Calgary, Alberta.
    Leal J; Vanderkooi OG; Church DL; Macdonald J; Tyrrell GJ; Kellner JD
    Pediatr Infect Dis J; 2012 Sep; 31(9):e169-75. PubMed ID: 22673137
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Impact of pneumococcal vaccination in Denmark during the first 3 years after PCV introduction in the childhood immunization programme.
    Ingels H; Rasmussen J; Andersen PH; Harboe ZB; Glismann S; Konradsen H; Hoffmann S; Valentiner-Branth P; Lambertsen L;
    Vaccine; 2012 Jun; 30(26):3944-50. PubMed ID: 22504662
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Impact of pneumococcal conjugate vaccines on burden of invasive pneumococcal disease and serotype distribution of Streptococcus pneumoniae isolates: an overview from Kuwait.
    Mokaddas E; Albert MJ
    Vaccine; 2012 Dec; 30 Suppl 6():G37-40. PubMed ID: 23228356
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Population-based surveillance for invasive pneumococcal disease and pneumonia in infants and young children in Bogotá, Colombia.
    Benavides JA; Ovalle OO; Salvador GR; Gray S; Isaacman D; Rodgers GL
    Vaccine; 2012 Aug; 30(40):5886-92. PubMed ID: 22484295
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 56.